Cargando…

Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study

Relapsed/refractory acute myeloid leukemia (RR-AML) are important types of hematological malignancy for which no effective salvage chemotherapy has been approved. The main purpose of this study was to determine the effectiveness of adding Bortezomib to salvage chemotherapy protocol in RR-AML patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghadiany, Mojtaba, Tabarraei, Mehdi, Varaminian, Beehnaz, Salari, Sina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842590/ https://www.ncbi.nlm.nih.gov/pubmed/35194425 http://dx.doi.org/10.22037/ijpr.2021.115475.15409

Ejemplares similares

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Metabolomics analysis of salvage chemotherapy on refractory acute myeloid leukemia patients
por: Zheng, Zhi, et al.
Publicado: (2018)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study
por: Xu, Jun, et al.
Publicado: (2018)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
por: Zhang, Chengtao, et al.
Publicado: (2023)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
por: Tabarraee, Mahdi, et al.
Publicado: (2023)

P578: EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL
por: Zhang, Chengtao, et al.
Publicado: (2023)

Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
por: da Silva, Wellington Fernandes, et al.
Publicado: (2020)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Erratum for: Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
Publicado: (2020)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
por: Martino, R, et al.
Publicado: (1998)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Anders, Brandi, et al.
Publicado: (2017)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Salvage treatment of relapsed/refractory LCH
por: Seo, Jong Jin
Publicado: (2016)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis
por: Wang, Zhong-yu, et al.
Publicado: (2022)

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2015)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
por: Hosono, Naoko, et al.
Publicado: (2021)

Treating second‐relapsed/refractory first‐relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
por: Merli, Pietro
Publicado: (2022)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
por: Schlenk, R F, et al.
Publicado: (2017)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2021)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_8b1dr2ujti7eri4j9tdqat3fbo